{"podcast":{"title":"Business Of Biotech","slug":"business-of-biotech-123501","podcast_index_feed_id":123501,"rss_url":"https://rss.buzzsprout.com/1011661.rss","website_url":"https://www.bioprocessonline.com/solution/the-business-of-biotech-podcast","image_url":"https://storage.buzzsprout.com/35u0bccu9j9xpr9zrrjias54otax?.jpg","author":"Ben Comer","episode_count":310,"summary":"The Business of Biotech is the pod dedicated to leaders of emerging biopharma firms. SUBSCRIBE to our new newsletter at www.bioprocessonline.com/bob. We bring you insight into organizational, finance and funding, HR, clinical, manufacturing, regulatory, and commercial challenges you’ll face as you navigate your company from an idea to success in the clinic and beyond. Each episode features guest commentary and best practices from accomplished founders and biopharma industry luminaries. The Business of Biotech is produced by Life Science Connect.","last_synced_at":"2026-06-08T22:18:30.179389+00:00","page_url":"https://stenobird.com/podcast/business-of-biotech-123501"},"episode":{"title":"A Royalty Model For Value Creation With Zymeworks' Kenneth Galbraith","slug":"a-royalty-model-for-value-creation-with-zymeworks-kenneth-galbraith","published_at":"2026-01-12T11:00:00+00:00","page_url":"https://stenobird.com/podcast/business-of-biotech-123501/a-royalty-model-for-value-creation-with-zymeworks-kenneth-galbraith","show_page_url":"https://stenobird.com/podcast/business-of-biotech-123501","url":"https://www.buzzsprout.com/1011661/episodes/18474370-a-royalty-model-for-value-creation-with-zymeworks-kenneth-galbraith.mp3","audio_url":"https://www.buzzsprout.com/1011661/episodes/18474370-a-royalty-model-for-value-creation-with-zymeworks-kenneth-galbraith.mp3","summary":"We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, we're speaking with Kenneth Galbraith, CEO and Board Chair at Zymeworks, a biotech developing multispecific therapies internally and through partnerships with companies including Jazz Pharmaceuticals and BeOne Medicines (formerly BeiGene), J&J, Merck, Daiichi Sankyo, and GSK. Ken talks about Zymeworks' shift to a royalty model for development funding and value creation, lessons learn...","meta_description":"We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, we're speaking with Kenneth Galbraith, CEO and B…","key_points":[],"chapters":[],"topics":[],"duration_seconds":3524,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/business-of-biotech-123501/episodes/a-royalty-model-for-value-creation-with-zymeworks-kenneth-galbraith/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/business-of-biotech-123501/a-royalty-model-for-value-creation-with-zymeworks-kenneth-galbraith.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}